Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
J Am Acad Dermatol 2024;90:82–90 doi: 10.1016/j.jaad.2023.08.097
Strober et al investigated skin clearance and treatment-related PROs in real-world patients treated with risankizumab from the North American CorEvitas Psoriasis Registry. Bio-experienced patients were more likely to have PsA, had a longer duration of psoriasis, and had a lower baseline BSA involvement compared with bio-naïve patients. Bio-naïve patients showed a slightly improved response across most outcomes compared with bio-experienced patients.
Keywords:
